Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Common Equity (2022 - 2025)

Historic Common Equity for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $7.4 million.

  • Addex Therapeutics' Common Equity fell 4166.22% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year decrease of 4166.22%. This contributed to the annual value of $11.0 million for FY2024, which is 76248.09% up from last year.
  • According to the latest figures from Q3 2025, Addex Therapeutics' Common Equity is $7.4 million, which was down 4166.22% from $8.7 million recorded in Q2 2025.
  • Addex Therapeutics' Common Equity's 5-year high stood at $14.0 million during Q1 2022, with a 5-year trough of -$1.6 million in Q1 2024.
  • For the 4-year period, Addex Therapeutics' Common Equity averaged around $7.5 million, with its median value being $7.4 million (2025).
  • Examining YoY changes over the last 5 years, Addex Therapeutics' Common Equity showed a top increase of 75545.03% in 2024 and a maximum decrease of 13573.67% in 2024.
  • Quarter analysis of 4 years shows Addex Therapeutics' Common Equity stood at $5.1 million in 2022, then plummeted by 74.68% to $1.3 million in 2023, then surged by 755.45% to $11.0 million in 2024, then crashed by 32.57% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, $8.7 million for Q2 2025, and $9.2 million during Q1 2025.